Skip to main content
Erschienen in: Journal of Clinical Immunology 4/2013

01.05.2013 | Original Research

Nodular Regenerative Hyperplasia in Common Variable Immunodeficiency

verfasst von: Ivan J. Fuss, Julia Friend, Zhiqiong Yang, Jian Ping He, Lubna Hooda, James Boyer, Liqiang Xi, Mark Raffeld, David E. Kleiner, Theo Heller, Warren Strober

Erschienen in: Journal of Clinical Immunology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Patients with Common Variable Immunodeficiency (CVID) are subject to the development of a liver disease syndrome known as nodular regenerative hyperplasia (NRH). The purpose of this study was to define the characteristics and course of this complication of CVID.

Methods

CVID patients were evaluated by retrospective and prospective clinical course review. Liver biopsy specimens were evaluated for evidence of NRH and studied via RT-PCR for cytokine analysis.

Results

NRH in our CVID patient population occurred in approximately 5 % of the 261 patients in our total CVID study group, initially presenting in most cases with an elevated alkaline phosphatase level. While in some patients the disease remained static, in a larger proportion a more severe disease developed characterized by portal hypertension, the latter leading to hypersplenism with neutropenia and thrombocytopenia and, in some cases, to ascites. In addition, a substantial proportion of patients either developed or presented initially with an autoimmune hepatitis-like (AIH-like) liver disease that resulted in severe liver dysfunction and, in most cases to death due to infections. The liver histologic findings in these AIH-like patients were characterized by underlying NRH pattern with superimposed interface hepatitis, lymphocytic infiltration and fibrosis. Immunologic studies of biopsies of NRH patients demonstrated the presence of infiltrating T cells producing IFN-γ, suggesting that the NRH is due to an autoimmune process.

Conclusion

Overall, these studies provide evidence that NRH may not be benign but, can be a severe and potentially fatal disease complication of CVID that merits close monitoring and intervention.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Moillot G, Jaussaud R, et al. DEFI Study Group. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46:1547–54.PubMedCrossRef Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Moillot G, Jaussaud R, et al. DEFI Study Group. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46:1547–54.PubMedCrossRef
2.
Zurück zum Zitat Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep. 2009;9:347–52.PubMedCrossRef Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep. 2009;9:347–52.PubMedCrossRef
3.
Zurück zum Zitat Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119:1650–7.PubMedCrossRef Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119:1650–7.PubMedCrossRef
4.
Zurück zum Zitat Cunningham-Rundles C, Radigan L, Knight AK, Bauer L, Nakazawa A. TLR9 activation is defective in common variable immune deficiency. J Immunol. 2006;176:1978–87.PubMed Cunningham-Rundles C, Radigan L, Knight AK, Bauer L, Nakazawa A. TLR9 activation is defective in common variable immune deficiency. J Immunol. 2006;176:1978–87.PubMed
5.
Zurück zum Zitat Salzer U, Grimbacher B. Common variable immunodeficiency: the power of co-stimulation. Semin Immunol. 2006;18:337–46.PubMedCrossRef Salzer U, Grimbacher B. Common variable immunodeficiency: the power of co-stimulation. Semin Immunol. 2006;18:337–46.PubMedCrossRef
6.
Zurück zum Zitat Giovanetti A, Pierdominici M, Mazzetta F, Marziali M, Renzi C, Mileo AM, et al. Unravelling the complexity of T cell abnormalities in common variable immunodefiency. J Immunol. 2007;178:3932–43. Giovanetti A, Pierdominici M, Mazzetta F, Marziali M, Renzi C, Mileo AM, et al. Unravelling the complexity of T cell abnormalities in common variable immunodefiency. J Immunol. 2007;178:3932–43.
7.
Zurück zum Zitat Busse PJ, Farzan S, Cunningham-Rundles C. Pulmonary complications of common variable immunodeficiency. Ann Allergy Asthma Immunol. 2007;98:8–11.CrossRef Busse PJ, Farzan S, Cunningham-Rundles C. Pulmonary complications of common variable immunodeficiency. Ann Allergy Asthma Immunol. 2007;98:8–11.CrossRef
8.
Zurück zum Zitat Knight A, Cunningham Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev. 2006;5:156–9.PubMedCrossRef Knight A, Cunningham Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev. 2006;5:156–9.PubMedCrossRef
9.
Zurück zum Zitat Mannon PJ, Fuss IJ, Friend J, Hornung R, Yang Z, Yi C, et al. Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency. Gastroenterology. 2006;13:748–56.CrossRef Mannon PJ, Fuss IJ, Friend J, Hornung R, Yang Z, Yi C, et al. Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency. Gastroenterology. 2006;13:748–56.CrossRef
10.
Zurück zum Zitat Malamut G, Verkarre V, Suarez F, Villard JF, Lascaux AS, Cosnes J, et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenteropathy. 2010;105:2262–75.CrossRef Malamut G, Verkarre V, Suarez F, Villard JF, Lascaux AS, Cosnes J, et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenteropathy. 2010;105:2262–75.CrossRef
11.
Zurück zum Zitat Malamut G, Ziol M, Suarez F, Beaugrand M, Viallard JF, Lascaus AS, et al. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol. 2008;48:74–82.PubMedCrossRef Malamut G, Ziol M, Suarez F, Beaugrand M, Viallard JF, Lascaus AS, et al. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol. 2008;48:74–82.PubMedCrossRef
12.
Zurück zum Zitat Ward C, Lucas M, Piris J, Collier J, Chapel H. Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia. Clin Exp Immunol. 2008;153:331–7.PubMedCrossRef Ward C, Lucas M, Piris J, Collier J, Chapel H. Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia. Clin Exp Immunol. 2008;153:331–7.PubMedCrossRef
13.
Zurück zum Zitat Wanless IR. Micronuodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990;11:787–97.PubMedCrossRef Wanless IR. Micronuodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990;11:787–97.PubMedCrossRef
14.
Zurück zum Zitat Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology. 2006;44:7–14.PubMedCrossRef Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology. 2006;44:7–14.PubMedCrossRef
15.
Zurück zum Zitat Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a T(H) 17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648–51.PubMedCrossRef Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a T(H) 17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648–51.PubMedCrossRef
16.
Zurück zum Zitat Lopatin U, Yao X, Williams RK, Blessing JJ, Dale JK, Wong D, et al. Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. Blood. 2001;97:3161–70.PubMedCrossRef Lopatin U, Yao X, Williams RK, Blessing JJ, Dale JK, Wong D, et al. Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. Blood. 2001;97:3161–70.PubMedCrossRef
17.
Zurück zum Zitat Quintanilla-Martinez L, Kumar S, Fend F, Reyes E, Teruya-Feldstein J, Kingma DW, et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood. 2000;96:443–51.PubMed Quintanilla-Martinez L, Kumar S, Fend F, Reyes E, Teruya-Feldstein J, Kingma DW, et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood. 2000;96:443–51.PubMed
18.
Zurück zum Zitat Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American group for immunodeficiency) and ESID (European society for immunodeficiencies). Clin Immunol. 1999;93:190–7.PubMedCrossRef Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American group for immunodeficiency) and ESID (European society for immunodeficiencies). Clin Immunol. 1999;93:190–7.PubMedCrossRef
19.
Zurück zum Zitat Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma and nodular regenerative hyperplasia: possible pathogenic relationship. Am J Gastroenterol. 1996;91:879–84.PubMed Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma and nodular regenerative hyperplasia: possible pathogenic relationship. Am J Gastroenterol. 1996;91:879–84.PubMed
20.
Zurück zum Zitat Ravindran J, Gillis D, Rowland R, Heddle R. Common variable immunodeficiency associated with nodular regenerative hyperplasia of the liver. Aust NZ J Med. 1995;25:741.CrossRef Ravindran J, Gillis D, Rowland R, Heddle R. Common variable immunodeficiency associated with nodular regenerative hyperplasia of the liver. Aust NZ J Med. 1995;25:741.CrossRef
21.
Zurück zum Zitat Ardeniz O, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Clin Immunol. 2009;133:198–207.PubMedCrossRef Ardeniz O, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Clin Immunol. 2009;133:198–207.PubMedCrossRef
22.
Zurück zum Zitat Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin Immunol. 2001;101:284–8.PubMedCrossRef Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin Immunol. 2001;101:284–8.PubMedCrossRef
23.
Zurück zum Zitat Shimamatsu K, Wanless IR. Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver. Hepatology. 1997;26:343–50.PubMedCrossRef Shimamatsu K, Wanless IR. Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver. Hepatology. 1997;26:343–50.PubMedCrossRef
24.
Zurück zum Zitat Ziol M, Poirel H, Koutchou GN, Boyer O, Mohand D, Mouthon L, et al. Intrasinusoidal cytotoxic CD8+ T cells in nodular regenerative hyperplasia of the liver. Hum Pathol. 2004;35:1241–51.PubMedCrossRef Ziol M, Poirel H, Koutchou GN, Boyer O, Mohand D, Mouthon L, et al. Intrasinusoidal cytotoxic CD8+ T cells in nodular regenerative hyperplasia of the liver. Hum Pathol. 2004;35:1241–51.PubMedCrossRef
Metadaten
Titel
Nodular Regenerative Hyperplasia in Common Variable Immunodeficiency
verfasst von
Ivan J. Fuss
Julia Friend
Zhiqiong Yang
Jian Ping He
Lubna Hooda
James Boyer
Liqiang Xi
Mark Raffeld
David E. Kleiner
Theo Heller
Warren Strober
Publikationsdatum
01.05.2013
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 4/2013
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-013-9873-6

Weitere Artikel der Ausgabe 4/2013

Journal of Clinical Immunology 4/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.